
Brian A Jackson / Shutterstock.com
15 May 2020PharmaBeatriz San Martin
Royalty Pharma: welcome clarity mixed with unwelcome ambiguity
At the end of April the Court of Justice of the European Union (CJEU) delivered its judgment in Case C-650/17 Royalty Pharma Collection Trust.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Pharma
15 October 2026 A dispute over missing experimental data and patent disclosures draws to a close as Boehringer and Dr Reddy’s deliver their final arguments. The court’s decision could bring greater clarity to the UK approach to plausibility and determine whether Dr Reddy’s can move ahead with its proposed generic launch.
Pharma
14 October 2026 Efforts to bring a generic cyanide poisoning treatment to market have suffered a setback after a US judge rejected challenges to three patents and criticised the drugmaker’s interpretation of the treatment’s chemical composition.
Pharma
13 October 2026 Generic challengers have scored a win against the Danish company after an appeals board revoked a key patent covering the cardiovascular use of semaglutide. The decision strips away another layer of protection as generic manufacturers hunt down the semaglutide franchise.
Editor's picks
Editor's picks
Regulation & Industry
17 September 2026
